Cost-effectiveness of continuous versus intermittent chemotherapy for patients with HER2-negative advanced breast cancer

References

• Claessens AKM, Bos M, Lopez-Yurda M, et al. Intermittent versus continuous first-line treatment for HER2-negative metastatic breast cancer: the stop & go study of the Dutch breast cancer research group (BOOG). Breast Cancer Res Treat. 2018;172(2):413–423.
   PubMed Web of Science ®Google Scholar
• Claessens AKM, Erdkamp FLG, Lopez-Yurda M, Dutch Breast Cancer Research Group (BOOG), et al. Secondary analyses of the randomized phase III stop&go study: efficacy of second-line intermittent versus continuous chemotherapy in HER2-negative advanced breast cancer. Acta Oncol. 2020;59(6):713–722.
   PubMed Web of Science ®Google Scholar
• Claessens AKM, Timman R, Busschbach JJ, et al. The influence on quality of life of intermittent scheduling in first- and second-line chemotherapy of patients with HER2-negative advanced breast cancer. Breast Cancer Res Treat. 2020;179(3):677–685.
   PubMed Web of Science ®Google Scholar
• Vondeling GT, Menezes GL, Dvortsin EP, et al. Burden of early, advanced and metastatic breast cancer in The Netherlands. BMC Cancer. 2018;18(1):262.
   PubMedGoogle Scholar
• Broekx S, Den Hond E, Torfs R, et al. The costs of breast cancer prior to and following diagnosis. Eur J Health Econ. 2011;12(4):311–317.
   PubMed Web of Science ®Google Scholar
• Campbell JD, Ramsey SD. The costs of treating breast cancer in the US: a synthesis of published evidence. Pharmacoeconomics. 2009;27(3):199–209.
   PubMed Web of Science ®Google Scholar
• Lamerato L, Havstad S, Gandhi S, et al. Economic burden associated with breast cancer recurrence: findings from a retrospective analysis of health system data. Cancer. 2006;106(9):1875–1882.
   PubMed Web of Science ®Google Scholar
• Mariotto AB, Yabroff KR, Shao Y, et al. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst. 2011;103(2):117–128.
   PubMed Web of Science ®Google Scholar
• Haas LC, Fernandes RA, Bines J, et al. Hormonal receptor positive, HER2 negative metastatic breast cancer (MBC HR + HER2-): pre and Post-Progression costs under the public health care system (SUS) and societal perspectives in Brazil. Value in Health. 2013;16(7):A404.
   Web of Science ®Google Scholar
• Allen JM. Economic/societal burden of metastatic breast cancer: a US perspective. Am J Manag Care. 2010;16(9):697–704.
   PubMed Web of Science ®Google Scholar
• Frederix GW, Severens JL, Hovels AM, et al. Time-dependent resource use and costs associated with different states of disease in patients diagnosed with HER-2-positive metastatic breast cancer. Breast Cancer Res Treat. 2013;139(2):489–495.
   PubMed Web of Science ®Google Scholar
• Rao S, Kubisiak J, Gilden D. Cost of illness associated with metastatic breast cancer. Breast Cancer Res Treat. 2004;83(1):25–32.
   PubMed Web of Science ®Google Scholar
• Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ. 2002;21(2):271–292.
   PubMed Web of Science ®Google Scholar
• Drummond MF, Sculpher MJ, Claxton K, et al. Methods for the economical evaluation of health care programmes. 4th ed. Oxford: Oxford University Press; 2015.
   Google Scholar
• Blank PR, Dedes KJ, Szucs TD. Cost effectiveness of cytotoxic and targeted therapy for metastatic breast cancer: a critical and systematic review. Pharmacoeconomics. 2010;28(8):629–647.
   PubMed Web of Science ®Google Scholar
• Barshes NR, Chambers JD, Cantor SB, et al. A primer on cost-effectiveness analyses for vascular surgeons. J Vasc Surg. 2012;55(6):1794–1800.
   PubMed Web of Science ®Google Scholar
• Zwaap J, Knies S, van der Meiden C, et al. Guideline for economic evaluations in healthcare. In: Institute NHC, editor. 2015. p. 1–40.
   Google Scholar
• Fenwick E, O'Brien BJ, Briggs A. Cost-effectiveness acceptability curves–facts, fallacies and frequently asked questions. Health Econ. 2004;13(5):405–415.
   PubMed Web of Science ®Google Scholar
• Miles DW, Chan A, Dirix LY, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2010;28(20):3239–3247.
   PubMed Web of Science ®Google Scholar
• Robert NJ, Dieras V, Glaspy J, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol. 2011;29(10):1252–1260.
   PubMed Web of Science ®Google Scholar
• Cardoso F, Senkus E, Costa A, et al. 4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4). Ann Oncol. 2018;29(8):1634–1657.
   PubMed Web of Science ®Google Scholar
• Gennari A, Stockler M, Puntoni M, et al. Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials. J Clin Oncol. 2011;29(16):2144–2149.
   PubMed Web of Science ®Google Scholar
• PASKWIL-criteria 2016: palliatieve behandeling [Internet]. Nationale vereneging voor medische oncologie (NVMO). 2016. Available from: https://www.nvmo.org/over-de-adviezen/.
   Google Scholar
• Claessens AKM, Ibragimova KIE, Geurts SME, et al. The role of chemotherapy in treatment of advanced breast cancer: an overview for clinical practice. Crit Rev Oncol Hematol. 2020; 153(153):102988.
   PubMedGoogle Scholar
• van Kampen RJW, Lobbezoo DJA, de Boer M, et al. A real-world study on implementation of bevacizumab in a cohort of HER2-negative metastatic breast cancer patients: a study of the southeast Netherlands breast cancer consortium. Cancer Treat Res Commun. 2017; 13:3–8.
   Google Scholar
• ZorgInstituutNederland(DutchHealthcareAuthority). Bevacizumab 2019 [updated 2019 Jun 12; cited 2021 Oct 5]; Version 1:[Description of agent and biosimilars, expected approval]. Available from: https://www.horizonscangeneesmiddelen.nl/geneesmiddelen/bevacizumab-oncologie-en-hematologie-oncologie-overig%5B2%5D/versie1.
   Google Scholar
• van Kampen RJW, Ramaekers BLT, Lobbezoo DJA, et al. Real-world and trial-based cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer patients: a study of the southeast Netherlands breast cancer consortium. Eur J Cancer. 2017;79:238–246.
   PubMed Web of Science ®Google Scholar
• Dedes KJ, Matter-Walstra K, Schwenkglenks M, et al. Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: an economic evaluation. Eur J Cancer. 2009;45(8):1397–1406.
   PubMed Web of Science ®Google Scholar